J B Chemicals & Pharmaceuticals Ltd
J B Chemicals & Pharmaceuticals Ltd Share Price Today: Live Updates & Key Insights
Get insights on J B Chemicals & Pharmaceuticals Ltd’s fundamentals, financials, shareholding, peer comparison, corporate actions & performance. Track key metrics, price trends & market sentiment for informed decisions. Explore all data at Motilal Oswal.
J B Chemicals & Pharmaceuticals Ltd Share Price Chart
J B Chemicals & Pharmaceuticals Ltd Fundamentals
Traded Volume: 2,64,543
Market Cap(Cr): 27,085
Avg Traded Price 1732.43
1 Year return 1.62%
Upper Circuit 1,748.4
Lower Circuit 1,720.6
P/E TTM 38.00
P/B Ratio 46.00
Traded Value(Cr) 4575.54
EPS TTM 45.866
Book value 45.866
Dividend 1.00%
J B Chemicals & Pharmaceuticals Ltd Share Price Performance
Shows the percentage change in stock price over different time periods
This section highlights J B Chemicals & Pharmaceuticals Ltd stock price performance across key timeframes, including 1-week, 1-month, 3-month, Year-To-Date (YTD), and 1-year returns. It provides insights into the J B Chemicals & Pharmaceuticals Ltd share price history, short-term movements, long-term trends, and overall investor sentiment
1W -4.89%
1M +2.27%
3M +0.09%
1Y +1.62%
YTD -6.91%
J B Chemicals & Pharmaceuticals Ltd Traded Volume Movement
Shows the trading volume over different time periods
This section highlights J B Chemicals & Pharmaceuticals Ltd daily and average traded volumes, offering insights into investor activity and market liquidity. Higher volumes than average often indicate rising interest, news impact, or shifting market sentiment
Yesterday 1.44L
Day Before Yesterday 2.74L
1W Avg 1.34L
1M Avg 2.04L
3M Avg 1.68L
J B Chemicals & Pharmaceuticals Ltd Technical Details
J B Chemicals & Pharmaceuticals Ltd technical indicators, such as support and resistance levels and pivot points, are calculated based on historical price and volume trends. These metrics help traders anticipate possible price movements and make informed trading decisions.
Support 1 1717
Support 2 1705
Support 3 1690
Pivot Point : 1733
Resistance 1 1745
Resistance 2 1761
Resistance 3 1773
J B Chemicals & Pharmaceuticals Ltd Corporate Actions
J B Chemicals & Pharmaceuticals Ltd corporate actions include dividends, bonus issues, stock splits, and key company updates that may affect share price and investor sentiment. This section provides timely details on past and upcoming actions, including ex-date, record date, and payout ratio - helping investors make informed decisions based on J B Chemicals & Pharmaceuticals Ltd’s capital allocation strategies.
All
Ex-Date 30-Jul-2025 Type D Description 7.00/share@700.00% Record Date 30-Jul-2025 Ratio 700.00
Ex-Date 07-Feb-2025 Type D Description 8.50/share@850.00% Record Date 08-Feb-2025 Ratio 850.00
Ex-Date 14-Aug-2024 Type D Description 6.75/share@675.00% Record Date 14-Aug-2024 Ratio 675.00
Ex-Date 16-Feb-2024 Type D Description 5.50/share@550.00% Record Date 16-Feb-2024 Ratio 550.00
Ex-Date 18-Sep-2023 Type S Description share@1:2.00 Record Date 18-Sep-2023 Ratio 1:2.00
Ex-Date 17-Aug-2023 Type D Description 9.25/share@462.50% Record Date 17-Aug-2023 Ratio 462.50
Ex-Date 17-Feb-2023 Type D Description 8.50/share@425.00% Record Date 18-Feb-2023 Ratio 425.00
Ex-Date 12-Aug-2022 Type D Description 8.00/share@400.00% Record Date 17-Aug-2022 Ratio 400.00
Ex-Date 23-Feb-2022 Type D Description 8.50/share@425.00% Record Date 24-Feb-2022 Ratio 425.00
Ex-Date 01-Sep-2021 Type D Description 8.00/share@400.00% Record Date 02-Sep-2021 Ratio 400.00
Ex-Date 18-Feb-2021 Type D Description 8.50/share@425.00% Record Date 22-Feb-2021 Ratio 425.00
Ex-Date 22-Sep-2020 Type D Description 1.00/share@50.00% Record Date 23-Sep-2020 Ratio 50.00
Ex-Date 03-Mar-2020 Type D Description 10.00/share@500.00% Record Date 04-Mar-2020 Ratio 500.00
Ex-Date 21-Nov-2019 Type T Description /share@% Record Date - Ratio
Ex-Date 14-Aug-2019 Type D Description 5.00/share@250.00% Record Date 16-Aug-2019 Ratio 250.00
Ex-Date 11-Sep-2018 Type T Description /share@% Record Date - Ratio
Ex-Date 27-Aug-2018 Type D Description 2.00/share@100.00% Record Date - Ratio 100.00
Ex-Date 11-Sep-2017 Type D Description 1.00/share@50.00% Record Date - Ratio 50.00
Ex-Date 01-Jun-2017 Type T Description /share@% Record Date - Ratio
Ex-Date 11-Aug-2016 Type D Description 0.50/share@25.00% Record Date - Ratio 25.00
Ex-Date 17-Mar-2016 Type D Description 4.50/share@225.00% Record Date 19-Mar-2016 Ratio 225.00
Ex-Date 06-Aug-2015 Type D Description 4.00/share@200.00% Record Date - Ratio 200.00
Ex-Date 06-Aug-2015 Type D Description 10.00/share@500.00% Record Date - Ratio 500.00
Ex-Date 04-Sep-2014 Type D Description 3.00/share@150.00% Record Date - Ratio 150.00
Ex-Date 01-Aug-2013 Type D Description 3.00/share@150.00% Record Date - Ratio 150.00
Ex-Date 19-Jul-2012 Type D Description 1.00/share@50.00% Record Date - Ratio 50.00
Ex-Date 29-Aug-2011 Type D Description 40.00/share@2000.00% Record Date 31-Aug-2011 Ratio 2000.00
Ex-Date 14-Jul-2011 Type D Description 2.00/share@100.00% Record Date - Ratio 100.00
Ex-Date 15-Jul-2010 Type D Description 2.00/share@100.00% Record Date - Ratio 100.00
Ex-Date 02-Jul-2009 Type D Description 1.00/share@50.00% Record Date - Ratio 50.00
Ex-Date 03-Jul-2008 Type D Description 0.50/share@25.00% Record Date - Ratio 25.00
Ex-Date 12-Jul-2007 Type D Description 1.50/share@75.00% Record Date - Ratio 75.00
Dividends
Announcement Date 30-Jul-2025 Ex Dividend Date 30-Jul-2025 Dividend(%) 700
Announcement Date 07-Feb-2025 Ex Dividend Date 07-Feb-2025 Dividend(%) 850
Announcement Date 14-Aug-2024 Ex Dividend Date 14-Aug-2024 Dividend(%) 675
Announcement Date 16-Feb-2024 Ex Dividend Date 16-Feb-2024 Dividend(%) 550
Announcement Date 17-Aug-2023 Ex Dividend Date 17-Aug-2023 Dividend(%) 463
Announcement Date 17-Feb-2023 Ex Dividend Date 17-Feb-2023 Dividend(%) 425
Announcement Date 12-Aug-2022 Ex Dividend Date 12-Aug-2022 Dividend(%) 400
Announcement Date 23-Feb-2022 Ex Dividend Date 23-Feb-2022 Dividend(%) 425
Announcement Date 01-Sep-2021 Ex Dividend Date 01-Sep-2021 Dividend(%) 400
Announcement Date 18-Feb-2021 Ex Dividend Date 18-Feb-2021 Dividend(%) 425
Announcement Date 22-Sep-2020 Ex Dividend Date 22-Sep-2020 Dividend(%) 50
Announcement Date 03-Mar-2020 Ex Dividend Date 03-Mar-2020 Dividend(%) 500
Announcement Date 14-Aug-2019 Ex Dividend Date 14-Aug-2019 Dividend(%) 250
Announcement Date 27-Aug-2018 Ex Dividend Date 27-Aug-2018 Dividend(%) 100
Announcement Date 11-Sep-2017 Ex Dividend Date 11-Sep-2017 Dividend(%) 50
Announcement Date 11-Aug-2016 Ex Dividend Date 11-Aug-2016 Dividend(%) 25
Announcement Date 17-Mar-2016 Ex Dividend Date 17-Mar-2016 Dividend(%) 225
Announcement Date 06-Aug-2015 Ex Dividend Date 06-Aug-2015 Dividend(%) 200
Announcement Date 06-Aug-2015 Ex Dividend Date 06-Aug-2015 Dividend(%) 500
Announcement Date 04-Sep-2014 Ex Dividend Date 04-Sep-2014 Dividend(%) 150
Announcement Date 01-Aug-2013 Ex Dividend Date 01-Aug-2013 Dividend(%) 150
Announcement Date 19-Jul-2012 Ex Dividend Date 19-Jul-2012 Dividend(%) 50
Announcement Date 29-Aug-2011 Ex Dividend Date 29-Aug-2011 Dividend(%) 2000
Announcement Date 14-Jul-2011 Ex Dividend Date 14-Jul-2011 Dividend(%) 100
Announcement Date 15-Jul-2010 Ex Dividend Date 15-Jul-2010 Dividend(%) 100
Announcement Date 02-Jul-2009 Ex Dividend Date 02-Jul-2009 Dividend(%) 50
Announcement Date 03-Jul-2008 Ex Dividend Date 03-Jul-2008 Dividend(%) 25
Announcement Date 12-Jul-2007 Ex Dividend Date 12-Jul-2007 Dividend(%) 75
Bonus
No Bonus has been declared by JBCHEPHARM
Splits
Record Date 18-Sep-2023 Split Date 18-Sep-2023 Face Value (Before/After) 2.00/1.00
Others
Ex-Rights Date 21-Nov-2019 Premium(Rs.) Ratio
Ex-Rights Date 11-Sep-2018 Premium(Rs.) Ratio
Ex-Rights Date 01-Jun-2017 Premium(Rs.) Ratio
J B Chemicals & Pharmaceuticals Ltd Peer Comparison
Shows key financial metrics for the company and its peers
This section compares J B Chemicals & Pharmaceuticals Ltd with leading peers in the banking sector based on key metrics such as market capitalization, 1-year return, P/E (TTM), and PB ratio. It helps investors evaluate J B Chemicals & Pharmaceuticals Ltd's relative performance and valuation against major competitors.
Stock Name Anthem Biosciences Ltd ₹635.10 (-1.91%) M. Cap (Cr) 356.68 1 Yr Return (%) NaN% P/E (TTM) 69.10 PB Ratio 14.80
Stock Name Ajanta Pharma Ltd ₹2485.70 (-1.00%) M. Cap (Cr) 310.55 1 Yr Return (%) -15.61% P/E (TTM) 31.89 PB Ratio 8.44
Stock Name Gland Pharma Ltd ₹1809.70 (-0.42%) M. Cap (Cr) 298.16 1 Yr Return (%) +1.27% P/E (TTM) 37.72 PB Ratio 3.26
Stock Name J B Chemicals & Pharmaceuticals Ltd ₹1729.60 (-1.08%) M. Cap (Cr) 270.85 1 Yr Return (%) +1.62% P/E (TTM) 37.71 PB Ratio 8.43
Stock Name Emcure Pharmaceuticals Ltd ₹1354.60 (-0.52%) M. Cap (Cr) 256.78 1 Yr Return (%) NaN% P/E (TTM) 32.38 PB Ratio 6.23
Stock Name Syngene International Ltd ₹629.25 (-0.84%) M. Cap (Cr) 253.55 1 Yr Return (%) -25.70% P/E (TTM) 54.15 PB Ratio 5.77
Stock Name Piramal Pharma Ltd ₹188.38 (-0.66%) M. Cap (Cr) 250.40 1 Yr Return (%) -23.39% P/E (TTM) -1054.76 PB Ratio 3.16
J B Chemicals & Pharmaceuticals Ltd Cash Flow
Cash flow data provides a view of how money is generated and spent by J B Chemicals & Pharmaceuticals Ltd, across its operating activities, investing activities, and financing activities.
PARTICULARS Operating Activities Mar 2025 884.03 Mar 2024 789.03 Mar 2023 628.64
PARTICULARS Investing Activities Mar 2025 -289.93 Mar 2024 -412.45 Mar 2023 -955.88
PARTICULARS Financing Activities Mar 2025 -574.27 Mar 2024 -374.08 Mar 2023 343.41
PARTICULARS Net Cash Flow Mar 2025 19.84 Mar 2024 2.49 Mar 2023 16.20
J B Chemicals & Pharmaceuticals Ltd Shareholding Pattern
This shows the ownership breakdown of J B Chemicals & Pharmaceuticals Ltd, highlighting participation from Foreign Institutional Investors (FII), Mutual Funds, Public, Other Institutions, and Promoters.
Promoter 47.56%
Public 14.31%
Other Institutions 3.68%
FII 15.31%
Mutual Funds 19.15%
About J B Chemicals & Pharmaceuticals Ltd
J B Chemicals & Pharmaceuticals Limited (JBC) was originally promoted and incorporated in Maharashtra by J B Mody as J B Mody Chemicals & Pharmaceuticals on December 18, 1976. The Company is engaged in the business of manufacturing and marketing of diverse range of pharmaceuticals formulations, herbal remedies and Active Pharmaceutical Ingredients (APIs). The company has manufacturing units at Thane, Belapur, Ankleshwar, Panoli and Daman. The bulk drug plant at Panoli and formulation plant at Daman became operational in Apr.'95. Products like metrogyl, rantac (a ranitidine-based formulation), and nicardia (a cardiac care medicine) form a significant part of the company's sales. JBC has its subsidiaries namely Lekar Healthcare Ltd and J.B Life Science Overseas Ltd. JBC had a tie-up with Justesa Imagen, Spain, to manufacture and market radio diagnostics under the Trazograf brand name. JBC has also diversified into high-growth agro-based products by acquiring McDa Agro (MAL). The products manufactured by MAL complement fertilisers and increase crop productivity. It has entered into a MoU with GNFC to distribute these products locally. The pharmaceutical divisions of Ifiunik Pharmaceuticals and Unique Pharmaceutical Laboratories has been merged into the company with effect from April 2000.Unique Chemicals (A Division of the company) manufacturing and marketing Bulk Drugs has been awarded Certificate of Suitability to Europeon Pharmacopoeia Monograph for Nifedipine EP from Europeon Directorate for the Quality Medicines.In Feb. 2002 the company has achieved another break through in its major R & D Activity - Invention biologically active molecules - New Chemical Entity. In 2001-02 the company introduced 3 products Reducin XX and two in the Cholesterol reducing segment i.e., Ifistatin and Vasolip. The company has launched five new products during the year 2003-04 in the global markets to widen its product portfolio. During 2004-05, the company launched new products Cephalosporins, Moviz and its expansion Movi 3D and a nueropsychiatry product through Zephyr for the first time.A 100% EOU manufacturing facility at Panoli for production of Gel, Ointment was commissioned during 2001-02 at a cost of Rs.21 crores and the same was financed through internal accruals. To manufacture 'DOKTOR MOM' lozenges the company is setting up two manufacturing units at Daman at a capital outlay of Rs.28 crores, which is to be financed through internal accruals. The commercial production of the Doktor Mom lozenges at its 100% Export Oriented Unit, started from 1 Sep. 2003 and tablets from 1, Jan. 2004 in Daman.Doktor Mom', the company's brand,was adjudged the Most Trusted European Brand by Reader's Digest in the cold and cough segment for the fourth consecutive year in 2003-04.During 2004-05, the company received approval for its pharmaceutical manufacturing unit from TGA (Australia). During 2004-05, the company plants were approved by US-FDA, TGA-Australia, EDQM, MCC-South Africa, INVIMA (Colombia) and MHRA (UK).During 2004-05, the company is setting up a new facility conforming to international standards in Panoli (Gujarat) to manufacture contrast media products by June 2006. During 2004-05, the company has planned to set up a wholly owned subsidiary in Moscow, Russia, called 'Unique Pharmaceuticals Laboratories' with the initial investment of $ 3 million.During 2005, the company entered into two agreements, one with Pharma-a-Care Pharmaceuticals Pte. Ltd., in Australia to develop its niche products in Australian market and another with Ranbaxy Laboratories to enter in the Romanian market.The company has subdivided the value of the share from Rs.10/- per share to Rs.2/- per share with effective from 05, April 2005.During 2005-2006, the company has proposed to amalgamate its wholly owned subsidiary viz. lekar healthcare ltd with itself. The company has fixed April 1, 2006 as the appointed date.During the year 2015, J.B. Chemicals & Pharmaceuticals Private Limited, Singapore, ceased to be the company's subsidiary consequent to its dissolution.The Scheme of Amalgamation and Arrangement between Jyotindra Mody Holdings Private Limited and Ansuya Mody Securities Private Limited and Dinesh Mody Securities Private Limited and Kumud Mody Securities Private Limited and Shirish B. Mody Investments Private Limited and Bharati S. Mody Investments Private Limited (Transferor Companies) and J. B. Chemicals & Pharmaceuticals Limited (Transferee Company) and their respective shareholders under Sections 391 to 394 read with Sections 100 to 103 of the Companies Act, 1956 and Section 55 of the Companies Act, 2013 and any other applicable provisions of the Companies Act, 1956 and the Companies Act, 2013, which was approved by the Board on 15 April 2014 and members of the company at Court Convened Meeting held on 14 October 2014 and public shareholders through postal ballot and e-voting on 16 October 2014, was sanctioned by the Hon'ble Bombay High Court on 27 February 2015. The Scheme has become effective on 13 April 2015 with appointed date of 1 April 2014. Accordingly, the Transferor Companies stand merged with the company and the merger has been given effect to in the financial statements of the company for the year ended on March 31, 2015. Consequently, 4,33,42,270 equity shares of FY Rs. 2 held by the Transferor Companies in the company have been cancelled and the company has allotted 4,33,42,270 equity shares of Rs. 2 each credited as fully paid up to the shareholders of the Transferor Companies in accordance with the fair share entitlement ratio specified in the Scheme.During the year 2016, the Company's subsidiary Unique Pharmaceutical Laboratories FZE (UPL FZE) acquired 2, 194,030 Ordinary Shares in Biotech Laboratories (Pty.) Ltd. from Afrika Biopharma Investments (Pty). Ltd. Consequent to restructuring of existing 49% shareholding in Biotech and issue of certain shares by Biotech after the aforesaid acquisition, UPL FZE now holds 95.24% voting capital of Biotech. Accordingly, Biotech has become subsidiary of the Company. Subsequently, the Company's subsidiary J.B. Healthcare Pvt. Ltd., Jersey, has been dissolved. With a view to return surplus cash and pursuant to authority conferred under the Articles of Association of the Company, the Board approved buy-back of fully paid up equity shares of face value of Rs 2 by the Company up to 12,50,000 equity shares at a price of Rs 400 per equity share for a total consideration not exceeding Rs 5,000 lakhs (buy-back amount) excluding transaction costs, on proportionate basis through tender offer. The number of equity shares authorized for buy-back represents 1.47% of the total outstanding equity shares, while the buy-back amount represents 3.85% of the equity share capital and free reserves as at March 31, 2017. This buy-back will be implemented in accordance with provisions of the Companies Act, 2013 and Securities and Exchange Board of India (Buy-back of Securities) Regulations, 1998.The Company completed on 25 July 2017 buy-back of 1,250,000 equity shares of face of Rs. 2 at price of Rs. 400 per share on proportionate basis through tender offer in accordance with provisions of the Companies Act, 2013 and Securities and Exchange Board of India (Buy-back of Securities) Regulations, 1998. Consequently, the paid-up equity share capital stands reduced to 83,569,975 equity shares of Rs. 2. The Company has transferred the sum of Rs. 25 lakhs from general reserves to capital redemption reserve account pursuant to Section 69 of the Companies Act, 2013.The Company launched four new products in dermatology, amoebicide and probiotic segments during the year 2018.The Company completed on 1st November 2018 buy-back of 3,333,333 equity shares of face value of Rs 2 at price of Rs 390 per share on proportionate basis through tender offer in accordance with provisions of the Companies Act, 2013 and Securities and Exchange Board of India (Buy-back of Securities) Regulations, 1998. Consequently, the paid-up equity share capital stands reduced to 80,236,642 equity shares of Rs 2. The Company has transferred the sum of Rs 66.67 lakhs from general reserve to capital redemption reserve account pursuant to Section 69 of the Companies Act, 2013.The Company launched six new products during the year 2020 across Cardiac and Gastrointestinal (GI) segments. On 2nd July, 2020, a Share Purchase Agreement was signed between founder, Mody Family members and Tau Investment Holdings Pte. Ltd., Singapore, an affiliate of global private equity firm KKR, where Tau Investment Holdings Pte. Ltd. acquired controlling stake of 41,731,363 (54%) equity shares of Rs. 2 each in the Company (JB Chemcials Pharmaceuticals Limited) from Mody Family members. Following execution of the above referred Share Purchase Agreement to acquire shares in and control over the Company, Tau Investment Holdings Pte. Ltd. and persons acting in concert made an open offer for acquiring 26% stake from public shareholders of the Company.In FY 2021, the Company introduced newer therapeutic categories for Diabetes, Nephrology, Respiratory and Virology. It launched 10 new products across angiotensin receptor blocker, anti-diabetic, calcium channel blocker, hypotensive, anti-peptic ulcerant, anti-viral and anti-parasitic segments.During the year 2022-23, the Company launched 17 new products in FY233 in the field of Gastro Intestinal, Gynaecology, Respiratory and Anti Diabetes. It acquired the `Azmarda' brand from Novartis, a niche Paediatric portfolio from Dr Reddy and the `Razel' franchise from Glenmark.
Non-Exec. & Independent Dir.
Padmini Khare Kaicker
Registered office Neelam Centre 4th Floor, B-Wing Hind Cycle Road Worli, Mumbai, Maharashtra, 400030
FAX :91-022-2482 2222/2493 0918
Background
Incorporation Year 1976
Face Value ₹1.00
Market Lot 1
FAQs on J B Chemicals & Pharmaceuticals Ltd
How to buy J B Chemicals & Pharmaceuticals Ltd shares on NSE?
To buy J B Chemicals & Pharmaceuticals Ltd shares in Motilal Oswal, you just need to open a demat account and get your KYC documents verified.
What is the J B Chemicals & Pharmaceuticals Ltd share price today?
The J B Chemicals & Pharmaceuticals Ltd share price on NSE is ₹1729.60 today.
What is the market cap of J B Chemicals & Pharmaceuticals Ltd on NSE?
The company has a market capitalization of ₹27084.89.
What is the PE & PB ratio of J B Chemicals & Pharmaceuticals Ltd?
PE is 38 and PB is 46.
What is the 52 Week High and Low of J B Chemicals & Pharmaceuticals Ltd shares?
J B Chemicals & Pharmaceuticals Ltd stock price high: ₹1952 J B Chemicals & Pharmaceuticals Ltd stock price low: ₹1385.75.